溶瘤病毒
溶癌病毒
组蛋白脱乙酰基酶
医学
不利影响
癌症
组蛋白脱乙酰酶抑制剂
癌症研究
药理学
生物
内科学
组蛋白
生物化学
基因
作者
Ekta Shirbhate,Ravichandran Veerasamy,Sai H. S. Boddu,Amit K. Tiwari,Harish Rajak
标识
DOI:10.1016/j.drudis.2022.02.009
摘要
A significant impediment to the treatment of solid and nonsolid cancers is the decline of drug efficacy and/or occurrence of adverse effects. In recent years, there has been increasing interest in oncolytic viruses (OVs) as a method to treat cancer because of their specificity for cancerous tissue and reduced likelihood of adverse effects. The results of clinical trials suggest that OVs have an acceptable safety profile and are effective in treating certain types of cancer, despite the limited number of these organisms. However, further advances are needed to make oncolytic virotherapy more effective by increasing tumor permeation and improving virus delivery. Combining oncolytic virotherapy with conventional treatments, such as targeted inhibitory drugs (e.g., histone deacetylase inhibitors), could results in safer, more reliable, and more effective therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI